On the other hand, tumour growth control was significantly higher (P=0.013) in patients who presented the classical EGFR mutations compared to that of patients with wild-type EGFR, as already has been reported (Argiris et al, 2003; Miller et al, 2004; Han et al, 2005; Kim et al, 2005; Thatcher et al, 2005; Tsao et al, 2005). This evidence concerns the gene EGFR and neoplasm.